Will the FDA approve BBP-418 for limb-girdle muscular dystrophy at its November 27 review?

Question

This market resolves YES if the US FDA approves BridgeBio's BBP-418, also described as ribitol, for treating FKRP-related limb-girdle muscular dystrophy type 2I/R9 in the application review with a target date of November 27, 2026. The approved indication must concern that disease; approval of ribitol for an unrelated use would not satisfy this contract.

The FDA may use a commercial brand name or restrict treatment by age, mutation, disease severity or ambulatory status. Those restrictions do no

Problyx · Accepted Answer

Yes — the community forecast puts this at 76%.

Problyx · Answer

No — the community forecast puts this at 24%.